US FDA Commissioner Scott Gottlieb stepping down

6 March 2019
gottlieb_fda_big-1

In a surprise announcement on Tuesday, it was revealed the US Food and Drug Administration Commissioner Scott Gottlieb would be stepping down from the post, in one month.

There was no explanation given for the decision, to abandon the position, which Dr Gottlieb took on just two years ago, with strong evidence of moving forward legislation on speeding up new drug as well as generics and biosimilars approval, among other things.

However, in a note tweeted by the FDA's official Twitter account, Dr Gottlieb cited family as the principal reason behind his decision.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical